# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Edward Tenthoff reiterates OPKO Health (NASDAQ:OPK) with a Overweight and maintains $3 price target.
HC Wainwright & Co. analyst Yi Chen reiterates OPKO Health (NASDAQ:OPK) with a Buy and maintains $3 price target.
The acquisition includes BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproducti...
Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:OPK) with a Outperform and raises the price target...
OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.09) by...
Opko Health shares are trading higher Thursday after the company announced a $100 million share repurchase program. Here's ...